hotspot -WSS

hotspot

author：comprehensive 2025-10-02 18:50:12 - browse：3235

Verve Therapeutics CEO Sekar Kathiresan Verve

SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines for rare, life-threatening diseases that generally affect small numbers of patients. But since Verve Therapeutics was founded in 2018, it’s had a wider aperture: using the molecular tools of genome editing to go after the most common cause of death in the world.

The plan, according to Verve CEO Sekar Kathiresan, is to edit out heart attacks for the millions of people at risk for severe cardiovascular disease. It’s a goal that’s more than a little audacious. There’s just one approved genome editing medicine, a treatment for sickle cell disease, and it only passed Food and Drug Administration review last month. Base editing, the CRISPR successor Verve uses to conduct its molecular surgery, is only a few years old.

“When we started, there were so many things that we were kind of going against the grain on,” Kathiresan told STAT at the J.P. Morgan Healthcare Conference in San Francisco this week. “In 2018, it was all about platforms, not about specific diseases and products, or taking this kind of idea for a large indication as opposed to cancer or rare disease. But we’ve always been motivated by a deep conviction in one simple research insight, which is that if your blood cholesterol is really low, lifelong, it is very hard to get a heart attack.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

leisure time

explore

WSS

How CO2 helps viruses stay alive longer in the air

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

The problem with charging patients to message their doctors

STAT wants to know your pick for a great summer read or listen

FTC loses bid to block Novant's North Carolina hospital merger

Structure Therapeutics oral GLP

hotspot

hotspot

focus

The high cost of giving birth even with insurance

Change Healthcare payments predicted restored March 15

BioMarin wins approval for gene therapy to treat hemophilia A

A new initiative will help leaders fight the next pandemic

Virginia high school admissions case could be legal follow

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

In age of alternative facts, a scholarly course on calling out crap

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Activists slam private health insurers over coverage restrictions

A deep dive into Applied Therapeutics’ data, and questions on Cassava

leisure time

In his State of the Union, Biden takes clear aim at 'Big Pharma'

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Sen. Paul opposes bill to ban Chinese biotechs

Precocious puberty in girls comes with mental health risks

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Headspace, Meta partner to launch VR meditation app for Quest

knowledge

leisure time

explore

leisure time